AstraZeneca splashes out $1.1 billion for Nasdaq-listed vaccine maker
Deal for novel respiratory vaccine-makerPrice represents a 91% premiumAdds to expertise in respiratory syncytial virusGlobal biopharmaceutical giant AstraZeneca (AZN) has agreed to purchase Nasdaq-listed vaccine maker Icosavax...
12 December 2023
